Valina L Dawson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3791571/publications.pdf

Version: 2024-02-01

371
papers

75,874
citations

576

129
h-index

636

264
g-index

413
all docs

413
docs citations

413
times ranked

72613
citing authors

#	Article	IF	Citations
1	CYFIP1 Dosages Exhibit Divergent Behavioral Impact via Diametric Regulation of NMDA Receptor Complex Translation in Mouse Models of Psychiatric Disorders. Biological Psychiatry, 2022, 92, 815-826.	0.7	8
2	ADPâ€ribosyltransferases, an update on function and nomenclature. FEBS Journal, 2022, 289, 7399-7410.	2.2	150
3	Intracellular Signaling. , 2022, , 74-81.e5.		0
4	Interleukin-6 triggers toxic neuronal iron sequestration in response to pathological Î±-synuclein. Cell Reports, 2022, 38, 110358.	2.9	18
5	Deubiquitinase CYLD acts as a negative regulator of dopamine neuron survival in Parkinsonâ€™s disease. Science Advances, 2022, 8, eabh1824.	4.7	12
6	STING mediates neurodegeneration and neuroinflammation in nigrostriatal Î±-synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2118819119.	3.3	64
7	A high-affinity cocaine binding site associated with the brain acid soluble protein 1. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200545119.	3.3	2
8	PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinsonâ€™s disease. Cell, 2022, 185, 1943-1959.e21.	13.5	36
9	Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinsonâ€™s disease. Neuron, 2022, 110, 2422-2437.e9.	3.8	64
10	Nanozyme scavenging ROS for prevention of pathologic Î±-synuclein transmission in Parkinsonâ€™s disease. Nano Today, 2021, 36, 101027.	6.2	78
11	Lymphocyte Activation Gene 3 (Lag3) Contributes to Î±-Synucleinopathy in Î±-Synuclein Transgenic Mice. Frontiers in Cellular Neuroscience, 2021, 15, 656426.	1.8	29
12	The cell biology of Parkinsonâ€™s disease. Journal of Cell Biology, 2021, 220, .	2.3	77
13	AIF3 splicing switch triggers neurodegeneration. Molecular Neurodegeneration, 2021, 16, 25.	4.4	3
14	Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 78.	2.4	82
15	Targeting Parthanatos in Ischemic Stroke. Frontiers in Neurology, 2021, 12, 662034.	1.1	28
16	Protocol for measurement of calcium dysregulation in human induced pluripotent stem cell-derived dopaminergic neurons. STAR Protocols, 2021, 2, 100405.	0.5	7
17	Mechanistic basis for receptor-mediated pathological Î±-synuclein fibril cell-to-cell transmission in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	59
18	Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa. ELife, 2021, 10, .	2.8	15

#	Article	IF	Citations
19	Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in Î±-Synuclein-Based Mouse Models of Parkinsonâ€™s Disease. Journal of Proteome Research, 2021, 20, 3428-3443.	1.8	21
20	PARIS farnesylation prevents neurodegeneration in models of Parkinsonâ€™s disease. Science Translational Medicine, 2021, 13, .	5.8	30
21	Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration. Brain, 2021, 144, 3674-3691.	3.7	13
22	LRRK2 Modulates the Exocyst Complex Assembly by Interacting with Sec8. Cells, 2021, 10, 203.	1.8	1
23	USP39 promotes non-homologous end-joining repair by poly(ADP-ribose)-induced liquid demixing. Nucleic Acids Research, 2021, 49, 11083-11102.	6.5	12
24	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. Pharmacological Reviews, 2021, 73, 1204-1268.	7.1	11
25	TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinsonâ€™s disease. Neuron, 2021, 109, 3758-3774.e11.	3.8	26
26	Waiting for PARISâ€”A Biological Target in Search of a Drug. Journal of Parkinson's Disease, 2021, , 1-9.	1.5	2
27	Integrative genome-wide analysis of dopaminergic neuron-specific PARIS expression in Drosophila dissects recognition of multiple PPAR-Î³ associated gene regulation. Scientific Reports, 2021, 11, 21500.	1.6	8
28	Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains. ENeuro, 2021, 8, ENEURO.0310-21.2021.	0.9	6
29	Recent advances in preventing neurodegenerative diseases. Faculty Reviews, 2021, 10, 81.	1.7	4
30	Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis. Cell Stem Cell, 2020, 27, 633-645.e7.	5.2	38
31	Meta-Analysis of the Alzheimerâ€™s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Reports, 2020, 32, 107908.	2.9	199
32	Determinants of seeding and spreading of Î±-synuclein pathology in the brain. Science Advances, 2020, 6, .	4.7	61
33	Microglia and astrocyte dysfunction in parkinson's disease. Neurobiology of Disease, 2020, 144, 105028.	2.1	177
34	Molecular Mediation of Prion-like Î±-Synuclein Fibrillation from Toxic PFFs to Nontoxic Species. ACS Applied Bio Materials, 2020, 3, 6096-6102.	2.3	8
35	Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons. Stem Cell Reports, 2020, 15, 629-645.	2.3	48
36	AMPA Receptor Surface Expression Is Regulated by S-Nitrosylation of Thorase and Transnitrosylation of NSF. Cell Reports, 2020, 33, 108329.	2.9	12

#	Article	IF	Citations
37	Development of a novel method for the quantification of tyrosine 39 phosphorylated Î±- and Î²-synuclein in human cerebrospinal fluid. Clinical Proteomics, 2020, 17, 13.	1.1	10
38	Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases. International Review of Cell and Molecular Biology, 2020, 353, 1-29.	1.6	63
39	PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency. Molecular Neurodegeneration, 2020, 15, 17.	4.4	58
40	PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2020, 15, 20.	4.4	264
41	Quantitative mass spectrometric analysis of the mouse cerebral cortex after ischemic stroke. PLoS ONE, 2020, 15, e0231978.	1.1	11
42	Integration of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons into Rat Brain. Bio-protocol, 2020, 10, e3746.	0.2	2
43	Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications, 2019, 7, 125.	2.4	47
44	Transneuronal Propagation of Pathologic Î±-Synuclein from the Gut to the Brain Models Parkinsonâ€™s Disease. Neuron, 2019, 103, 627-641.e7.	3.8	830
45	Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinsonâ€™s disease. Brain, 2019, 142, 2380-2401.	3.7	46
46	The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration. Movement Disorders, 2019, 34, 959-969.	2.2	68
47	Fyn kinase regulates misfolded Î±-synuclein uptake and NLRP3 inflammasome activation in microglia. Journal of Experimental Medicine, 2019, 216, 1411-1430.	4.2	169
48	Neurons Derived from Human Induced Pluripotent Stem Cells Integrate into Rat Brain Circuits and Maintain Both Excitatory and Inhibitory Synaptic Activities. ENeuro, 2019, 6, ENEURO.0148-19.2019.	0.9	16
49	Promising disease-modifying therapies for Parkinsonâ€™s disease. Science Translational Medicine, 2019, 11, .	5.8	46
50	Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons. Stem Cells Translational Medicine, 2019, 8, 112-123.	1.6	39
51	The AAAâ€‰+â€‰ATPase Thorase is neuroprotective against ischemic injury. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1836-1848.	2.4	10
52	Nitric Oxide Signaling in Neurodegeneration and Cell Death. Advances in Pharmacology, 2018, 82, 57-83.	1.2	65
53	DISC1 regulates lactate metabolism in astrocytes: implications for psychiatric disorders. Translational Psychiatry, 2018, 8, 76.	2.4	34
54	A homozygous ATAD1 mutation impairs postsynaptic AMPA receptor trafficking and causes a lethal encephalopathy. Brain, 2018, 141, 651-661.	3.7	52

#	Article	IF	Citations
55	Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1635-1640.	3.3	70
56	Pathological Endogenous Î±-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy. Stem Cell Reports, 2018, 10, 356-365.	2.3	61
57	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	5.0	4,036
58	GBA1 deficiency negatively affects physiological Î±-synuclein tetramers and related multimers. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 798-803.	3.3	139
59	Opportunities for the repurposing of PARP inhibitors for the therapy of nonâ€oncological diseases. British Journal of Pharmacology, 2018, 175, 192-222.	2.7	160
60	Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases. Cell Death and Differentiation, 2018, 25, 542-572.	5.0	120
61	Poly(ADP-ribose) drives pathologic Î±-synuclein neurodegeneration in Parkinsonâ€™s disease. Science, 2018, 362, .	6.0	317
62	The PINK1 p.I368N Mutation Affects Protein Stability and Kinase Activity with Its Structural Change. Juntendo Medical Journal, 2018, 64, 17-30.	0.1	0
63	Reply: ATAD1 encephalopathy and stiff baby syndrome: a recognizable clinical presentation. Brain, 2018, 141, e50-e50.	3.7	1
64	Excitotoxic Programmed Cell Death Involves Caspase-Independent Mechanisms. , 2018, , 3-17.		2
65	Î±-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Molecular Neurodegeneration, 2018, 13, 1.	4.4	143
66	Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. Molecular Neurodegeneration, 2018, 13, 8.	4.4	87
67	Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinsonâ€™s disease. Nature Medicine, 2018, 24, 931-938.	15.2	712
68	Synaptic Plasticity onto Dopamine Neurons Shapes Fear Learning. Neuron, 2017, 93, 425-440.	3.8	45
69	Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 2017, 541, 481-487.	13.7	4,977
70	Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics. Annual Review of Pharmacology and Toxicology, 2017, 57, 437-454.	4.2	120
71	PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. Cell Reports, 2017, 18, 918-932.	2.9	141
72	Precision therapy for a new disorder of AMPA receptor recycling due to mutations in <i>ATAD1</i>. Neurology: Genetics, 2017, 3, e130.	0.9	40

#	ARTICLE	IF	CITATIONS
73	The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Molecular Neurodegeneration, 2017, 12, 32.	4.4	62
74	Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes. Experimental Neurology, 2017, 298, 191-201.	2.0	55
75	T cells from patients with Parkinsonâ€™s disease recognize Î±-synuclein peptides. Nature, 2017, 546, 656-661.	13.7	618
76	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. Brain, 2017, 140, e33-e33.	3.7	2
77	Models of LRRK2-Associated Parkinsonâ€™s Disease. Advances in Neurobiology, 2017, 14, 163-191.	1.3	50
78	Activation mechanisms of the E3 ubiquitin ligase parkin. Biochemical Journal, 2017, 474, 3075-3086.	1.7	47
79	Toward the human cellular microRNAome. Genome Research, 2017, 27, 1769-1781.	2.4	142
80	Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel. Science Translational Medicine, 2017, 9, .	5.8	20
81	Two approaches reveal a new paradigm of â€˜switchable or genetics-influenced allele-specific DNA methylationâ€™ with potential in human disease. Cell Discovery, 2017, 3, 17038.	3.1	25
82	Cell Death Mechanisms of Neurodegeneration. Advances in Neurobiology, 2017, 15, 403-425.	1.3	90
83	Heterozygous PINK1 p.G411S increases risk of Parkinsonâ€™s disease via a dominant-negative mechanism. Brain, 2017, 140, 98-117.	3.7	116
84	Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1982-1993.	2.4	20
85	c-Abl and Parkinsonâ€™s Disease: Mechanisms and Therapeutic Potential. Journal of Parkinson's Disease, 2017, 7, 589-601.	1.5	67
86	Overexpression of Parkinsonâ€™s Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and Î±-Synuclein Pathology. ENeuro, 2017, 4, ENEURO.0004-17.2017.	0.9	31
87	LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity. Journal of Chemical Neuroanatomy, 2016, 76, 90-97.	1.0	36
88	Pathological Î±-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science, 2016, 353, .	6.0	521
89	A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science, 2016, 354, .	6.0	266
90	LRRK2 pathobiology in Parkinson's disease â€“ virtual inclusion. Journal of Neurochemistry, 2016, 139, 75-76.	2.1	5

#	ARTICLE	IF	CITATIONS
91	Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity. Science Translational Medicine, 2016, 8, 333ra48.	5.8	66
92	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
93	Intracellular Signaling. , 2016, , 80-89.		0
94	Activation of tyrosine kinase c-Abl contributes to Î±-synucleinâ€"induced neurodegeneration. Journal of Clinical Investigation, 2016, 126, 2970-2988.	3.9	133
95	Adult Conditional Knockout of PGC-1Î± Leads to Loss of Dopamine Neurons. ENeuro, 2016, 3, ENEURO.0183-16.2016.	0.9	87
96	High-Content Genome-Wide RNAi Screen Reveals<i>CCR3</i>as a Key Mediator of Neuronal Cell Death. ENeuro, 2016, 3, ENEURO.0185-16.2016.	0.9	15
97	(Pathoâ€)physiological relevance of <scp>PINK</scp> 1â€dependent ubiquitin phosphorylation. EMBO Reports, 2015, 16, 1114-1130.	2.0	147
98	Lysosomal Enzyme Glucocerebrosidase Protects against AÎ²1-42 Oligomer-Induced Neurotoxicity. PLoS ONE, 2015, 10, e0143854.	1.1	12
99	TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinsonâ€™s disease via CNTF. Brain, 2015, 138, 3610-3622.	3.7	95
100	Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11696-11701.	3.3	207
101	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death and Differentiation, 2015, 22, 58-73.	5.0	811
102	Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. Human Molecular Genetics, 2014, 23, 2055-2077.	1.4	113
103	Abberant protein synthesis in G2019S LRRK2<i>Drosophila</i>Parkinson disease-related phenotypes. Fly, 2014, 8, 165-169.	0.9	19
104	<scp>M</scp>sp1/<scp>ATAD</scp>1 maintains mitochondrial function by facilitating the degradation of mislocalized tailâ€anchored proteins. EMBO Journal, 2014, 33, 1548-1564.	3.5	172
105	Protein Microarray Characterization of the S-Nitrosoproteome. Molecular and Cellular Proteomics, 2014, 13, 63-72.	2.5	56
106	LRRK2 pathobiology in Parkinson's disease. Journal of Neurochemistry, 2014, 131, 554-565.	2.1	131
107	Proneural Transcription Factor Atoh1 Drives Highly Efficient Differentiation of Human Pluripotent Stem Cells Into Dopaminergic Neurons. Stem Cells Translational Medicine, 2014, 3, 888-898.	1.6	35
108	Motor Neuron Death in ALS: Programmed by Astrocytes?. Neuron, 2014, 81, 961-963.	3.8	23

#	ARTICLE	IF	CITATIONS
109	MicroRNA-132 dysregulation in Toxoplasma gondii infection has implications for dopamine signaling pathway. Neuroscience, 2014, 268, 128-138.	1.1	93
110	Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinsonâ€™s Disease. Cell, 2014, 157, 472-485.	13.5	239
111	Parkin and PINK1: much more than mitophagy. Trends in Neurosciences, 2014, 37, 315-324.	4.2	309
112	Parkin Plays a Role in Sporadic Parkinson's Disease. Neurodegenerative Diseases, 2014, 13, 69-71.	0.8	74
113	Early-onset Parkinson's disease due to PINK1 p.Q456X mutation â€“ Clinical and functional study. Parkinsonism and Related Disorders, 2014, 20, 1274-1278.	1.1	41
114	Parkinâ€independent mitophagy requires <scp>D</scp>rp1 and maintains the integrity of mammalian heart and brain. EMBO Journal, 2014, 33, 2798-2813.	3.5	361
115	Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10209-10214.	3.3	253
116	Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinsonâ€™s-like movement disorder. Nature Communications, 2014, 5, 4930.	5.8	118
117	Ganglioside Regulation of AMPA Receptor Trafficking. Journal of Neuroscience, 2014, 34, 13246-13258.	1.7	45
118	MiR-223 regulates the differentiation of immature neurons. Molecular and Cellular Therapies, 2014, 2, 18.	0.2	24
119	Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiology of Disease, 2014, 71, 345-358.	2.1	59
120	Parthanatos: mitochondrialâ€linked mechanisms and therapeutic opportunities. British Journal of Pharmacology, 2014, 171, 2000-2016.	2.7	432
121	Botch Is a Î³-Glutamyl Cyclotransferase that Deglycinates and Antagonizes Notch. Cell Reports, 2014, 7, 681-688.	2.9	29
122	The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Scientific Reports, 2014, 4, 4874.	1.6	188
123	Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nature Neuroscience, 2013, 16, 1392-1400.	7.1	182
124	Reprogramming cellular events by poly(ADP-ribose)-binding proteins. Molecular Aspects of Medicine, 2013, 34, 1066-1087.	2.7	141
125	Usp16: key controller of stem cells in Down syndrome. EMBO Journal, 2013, 32, 2788-2789.	3.5	6
126	New synaptic and molecular targets for neuroprotection in Parkinson's disease. Movement Disorders, 2013, 28, 51-60.	2.2	34

#	ARTICLE	IF	CITATIONS
127	Sulfhydration mediates neuroprotective actions of parkin. Nature Communications, 2013, 4, 1626.	5.8	265
128	The interplay of microRNA and neuronal activity in health and disease. Frontiers in Cellular Neuroscience, 2013, 7, 136.	1.8	50
129	Identification through highâ€throughput screening of 4'â€methoxyflavone and 3',4'â€dimethoxyflavone as novel neuroprotective inhibitors of parthanatos. British Journal of Pharmacology, 2013, 169, 1263-1278.	2.7	34
130	LRRK2 Affects Vesicle Trafficking, Neurotransmitter Extracellular Level and Membrane Receptor Localization. PLoS ONE, 2013, 8, e77198.	1.1	66
131	Ironing out tau's role in parkinsonism. Nature Medicine, 2012, 18, 197-198.	15.2	13
132	ArfGAP1 Is a GTPase Activating Protein for LRRK2: Reciprocal Regulation of ArfGAP1 by LRRK2. Journal of Neuroscience, 2012, 32, 3877-3886.	1.7	92
133	Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. Human Molecular Genetics, 2012, 21, 163-174.	1.4	34
134	Animal Models of Parkinson's Disease: Vertebrate Genetics. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009324-a009324.	2.9	99
135	Neurodegenerative phenotypes in an A53T Â-synuclein transgenic mouse model are independent of LRRK2. Human Molecular Genetics, 2012, 21, 2420-2431.	1.4	84
136	Development and Characterization of a New Parkinson's Disease Model Resulting from Impaired Autophagy. Journal of Neuroscience, 2012, 32, 16503-16509.	1.7	124
137	LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. Biochemical Society Transactions, 2012, 40, 1074-1079.	1.6	21
138	MicroRNA-223 is neuroprotective by targeting glutamate receptors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18962-18967.	3.3	245
139	Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends in Pharmacological Sciences, 2012, 33, 365-373.	4.0	69
140	Botch Promotes Neurogenesis by Antagonizing Notch. Developmental Cell, 2012, 22, 707-720.	3.1	54
141	Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death and Differentiation, 2012, 19, 107-120.	5.0	2,144
142	Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, 141ra90.	5.8	444
143	Measuring the Activity of Leucine-Rich Repeat Kinase 2: A Kinase Involved in Parkinsonâ€™s Disease. Methods in Molecular Biology, 2012, 795, 45-54.	0.4	2
144	Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinsonâ€™s Disease-Related Toxicity in Human Neurons. ACS Chemical Biology, 2011, 6, 1021-1028.	1.6	131

#	ARTICLE	IF	CITATIONS
145	PARIS (ZNF746) Repression of PGC-1Î± Contributes to Neurodegeneration in Parkinson's Disease. Cell, 2011, 144, 689-702.	13.5	796
146	The AAA+ ATPase Thorase Regulates AMPA Receptor-Dependent Synaptic Plasticity and Behavior. Cell, 2011, 145, 284-299.	13.5	88
147	Poly(ADP-Ribose) (PAR) Binding to Apoptosis-Inducing Factor Is Critical for PAR Polymerase-1â€"Dependent Cell Death (Parthanatos). Science Signaling, 2011, 4, ra20.	1.6	360
148	MicroRNAs in Parkinson's disease. Journal of Chemical Neuroanatomy, 2011, 42, 127-130.	1.0	142
149	Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2. PLoS ONE, 2011, 6, e18568.	1.1	338
150	Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nature Medicine, 2011, 17, 692-699.	15.2	190
151	Recent Advances in the Genetics of Parkinson's Disease. Annual Review of Genomics and Human Genetics, 2011, 12, 301-325.	2.5	355
152	Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14103-14108.	3.3	205
153	A Lysosomal Lair for a Pathogenic Protein Pair. Science Translational Medicine, 2011, 3, 91ps28.	5.8	11
154	Enhanced Autophagy from Chronic Toxicity of Iron and Mutant A53T Î±-Synuclein. Journal of Biological Chemistry, 2011, 286, 33380-33389.	1.6	82
155	Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Human Molecular Genetics, 2011, 20, 3933-3942.	1.4	120
156	Resistance to MPTP-Neurotoxicity in Î±-Synuclein Knockout Mice Is Complemented by Human Î±-Synuclein and Associated with Increased Î²-Synuclein and Akt Activation. PLoS ONE, 2011, 6, e16706.	1.1	57
157	Neuronal Activity Regulates Hippocampal miRNA Expression. PLoS ONE, 2011, 6, e25068.	1.1	48
158	Intracellular Signaling: Mediators and Protective Responses. , 2011, , 154-161.		0
159	The role of parkin in familial and sporadic Parkinson's disease. Movement Disorders, 2010, 25, S32-9.	2.2	309
160	Contributions of poly(ADPâ€•ribose) polymeraseâ€•1 and â€•2 to nuclear translocation of apoptosisâ€•inducing factor and injury from focal cerebral ischemia. Journal of Neurochemistry, 2010, 113, 1012-1022.	2.1	51
161	Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine, 2010, 16, 998-1000.	15.2	342
162	NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. Journal of Clinical Investigation, 2010, 120, 2446-2456.	3.9	42

#	ARTICLE	IF	CITATIONS
163	Reevaluation of Phosphorylation Sites in the Parkinson Disease-associated Leucine-rich Repeat Kinase 2. Journal of Biological Chemistry, 2010, 285, 29569-29576.	1.6	48
164	Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16691-16696.	3.3	241
165	PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 378-383.	3.3	1,415
166	Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R215-R221.	0.9	18
167	GTPase Activity Plays a Key Role in the Pathobiology of LRRK2. PLoS Genetics, 2010, 6, e1000902.	1.5	177
168	The impact of genetic research on our understanding of Parkinsonâ€™s disease. Progress in Brain Research, 2010, 183, 21-41.	0.9	26
169	Neonatal Stroke in Mice Causes Long-Term Changes in Neuronal Notch-2 Expression That May Contribute to Prolonged Injury. Stroke, 2010, 41, S64-71.	1.0	23
170	Genetic Animal Models of Parkinson's Disease. Neuron, 2010, 66, 646-661.	3.8	714
171	Functional Identification of Neuroprotective Molecules. PLoS ONE, 2010, 5, e15008.	1.1	31
172	Excitotoxic Programmed Cell Death Involves Caspase-Independent Mechanisms. , 2010, , 79-88.		1
173	S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4900-4905.	3.3	141
174	CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2897-2902.	3.3	195
175	Parkin Protects against LRRK2 G2019S Mutant-Induced Dopaminergic Neurodegeneration in Drosophila. Journal of Neuroscience, 2009, 29, 11257-11262.	1.7	193
176	Outer Mitochondrial Membrane Localization of Apoptosis-Inducing Factor: Mechanistic Implications for Release. ASN Neuro, 2009, 1, AN20090046.	1.5	69
177	Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radical Biology and Medicine, 2009, 47, 1049-1056.	1.3	55
178	Conditional transgenic mice expressing C-terminally truncated human Î±-synuclein (Î±Syn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Molecular Neurodegeneration, 2009, 4, 34.	4.4	79
179	Understanding microRNAs in neurodegeneration. Nature Reviews Neuroscience, 2009, 10, 837-841.	4.9	256
180	Calpain activation is not required for AIF translocation in PARPâ€1â€dependent cell death (parthanatos). Journal of Neurochemistry, 2009, 110, 687-696.	2.1	89

#	ARTICLE	IF	CITATIONS
181	Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine). Journal of Neuroscience, 2009, 29, 15846-15850.	1.7	114
182	Poly(ADP-ribose) signals to mitochondrial AIF: A key event in parthanatos. Experimental Neurology, 2009, 218, 193-202.	2.0	327
183	SnapShot: Pathogenesis of Parkinson's Disease. Cell, 2009, 139, 440.e1-440.e2.	13.5	12
184	Abnormal Localization of Leucine-Rich Repeat Kinase 2 to the Endosomal-Lysosomal Compartment in Lewy Body Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 994-1005.	0.9	75
185	Parthanatos, a messenger of death. Frontiers in Bioscience - Landmark, 2009, Volume, 1116.	3.0	330
186	Mitochondrial and Nuclear Cross Talk in Cell Death. Annals of the New York Academy of Sciences, 2008, 1147, 233-241.	1.8	284
187	Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nature Cell Biology, 2008, 10, 866-873.	4.6	353
188	Parkin mediates the degradationâ€independent ubiquitination of Hsp70. Journal of Neurochemistry, 2008, 105, 1806-1819.	2.1	101
189	Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Human Molecular Genetics, 2008, 17, 2570-2582.	1.4	143
190	Advances in Neuronal Cell Death 2007. Stroke, 2008, 39, 286-288.	1.0	36
191	Lysine 63-linked polyubiquitin potentially partners with p62 to promote the clearance of protein inclusions by autophagy. Autophagy, 2008, 4, 251-253.	4.3	54
192	The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2. Journal of Neuroscience, 2008, 28, 3384-3391.	1.7	178
193	Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Research, 2008, 36, 6959-6976.	6.5	359
194	Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Human Molecular Genetics, 2008, 17, 431-439.	1.4	379
195	What causes cell death in Parkinson's disease?. Annals of Neurology, 2008, 64, S3-S15.	2.8	95
196	Genetic Models of Familial Parkinson's Disease. , 2008, , 225-236.		0
197	Parthanatos. , 2008, , 143-156.		1
198	Ataxia Telangiectasia Mutated (ATM) Signaling Network Is Modulated by a Novel Poly(ADP-ribose)-dependent Pathway in the Early Response to DNA-damaging Agents. Journal of Biological Chemistry, 2007, 282, 16441-16453.	1.6	225

#	ARTICLE	IF	CITATIONS
199	DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14807-14812.	3.3	435
200	Parkinson Disease: Molecular Insights. , 2007, , 221-239.		0
201	Relative Sensitivity of Parkin and Other Cysteine-containing Enzymes to Stress-induced Solubility Alterations. Journal of Biological Chemistry, 2007, 282, 12310-12318.	1.6	75
202	Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Human Molecular Genetics, 2007, 16, 223-232.	1.4	535
203	Parkinson's disease genetic mutations increase cell susceptibility to stress: Mutant Î±-synuclein enhances H2O2- and Sin-1-induced cell death. Neurobiology of Aging, 2007, 28, 1709-1717.	1.5	53
204	Influence of duration of focal cerebral ischemia and neuronal nitric oxide synthase on translocation of apoptosis-inducing factor to the nucleus. Neuroscience, 2007, 144, 56-65.	1.1	40
205	Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain. Neuroscience, 2007, 148, 198-211.	1.1	34
206	Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. Journal of Neurochemistry, 2007, 100, 368-381.	2.1	101
207	Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neuroscience, 2007, 8, 102.	0.8	135
208	Localization of Parkinsonâ€™s disease-associated LRRK2 in normal and pathological human brain. Brain Research, 2007, 1155, 208-219.	1.1	139
209	MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiology of Disease, 2007, 26, 312-322.	2.1	64
210	Parkin-mediated lysine 63-linked polyubiquitination: A link to protein inclusions formation in Parkinson's and other conformational diseases?. Neurobiology of Aging, 2006, 27, 524-529.	1.5	130
211	Diagnosis and treatment of Parkinson disease: molecules to medicine. Journal of Clinical Investigation, 2006, 116, 1744-1754.	3.9	538
212	Mining for survival genes. Biochemical Society Transactions, 2006, 34, 1307-1309.	1.6	4
213	Taming the clot-buster tPA. Nature Medicine, 2006, 12, 993-994.	15.2	8
214	Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Neuroscience, 2006, 9, 1231-1233.	7.1	587
215	EndoG is dispensable in embryogenesis and apoptosis. Cell Death and Differentiation, 2006, 13, 1147-1155.	5.0	81
216	Differential Effect of PARP-2 Deletion on Brain Injury after Focal and Global Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2006, 26, 135-141.	2.4	63

#	Article	IF	Citations
217	Role of nitric oxide in Parkinson's disease. , 2006, 109, 33-41.		150
218	Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Annals of Neurology, 2006, 60, 557-569.	2.8	479
219	Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3887-3889.	3.3	222
220	Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18314-18319.	3.3	655
221	Identification of Far Upstream Element-binding Protein-1 as an Authentic Parkin Substrate. Journal of Biological Chemistry, 2006, 281, 16193-16196.	1.6	91
222	Inclusion Body Formation and Neurodegeneration Are Parkin Independent in a Mouse Model of Â-Synucleinopathy. Journal of Neuroscience, 2006, 26, 3685-3696.	1.7	86
223	Poly(ADP-ribose) (PAR) polymer is a death signal. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18308-18313.	3.3	572
224	PARP and the Release of Apoptosis-Inducing Factor from Mitochondria. , 2006, , 103-117.		4
225	Lessons from Drosophila Models of DJ-1 Deficiency. Science of Aging Knowledge Environment: SAGE KE, 2006, 2006, pe2-pe2.	0.9	27
226	The involvement of nitric oxide in the enhanced expression of Î¼ -opioid receptors during intestinal inflammation in mice. British Journal of Pharmacology, 2005, 145, 758-766.	2.7	29
227	The role of nitric oxide and PARP in neuronal cell death. , 2005, , 146-156.		0
228	Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Human Molecular Genetics, 2005, 14, 2571-2586.	1.4	200
229	Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Human Molecular Genetics, 2005, 14, 71-84.	1.4	231
230	Response to Comment on "S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function". Science, 2005, 308, 1870c-1870c.	6.0	20
231	Bcl-x Is Required for Proper Development of the Mouse Substantia Nigra. Journal of Neuroscience, 2005, 25, 6721-6728.	1.7	140
232	Sâ€Nitrosylation in Parkinson's Disease and Related Neurodegenerative Disorders. Methods in Enzymology, 2005, 396, 139-150.	0.4	38
233	Identification and Evaluation of NOâ€Regulated Genes by Differential Analysis of Primary cDNA Library Expression (DAzLE). Methods in Enzymology, 2005, 396, 359-368.	0.4	1
234	Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18676-18681.	3.3	390

#	Article	IF	Citations
235	Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation. Journal of Neuroscience, 2005, 25, 2002-2009.	1.7	489
236	Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death. Journal of Neuroscience, 2005, 25, 7968-7978.	1.7	221
237	The Road to Survival Goes through PARG. Cell Cycle, 2005, 4, 397-399.	1.3	21
238	Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Human Molecular Genetics, 2005, 14, 3885-3897.	1.4	201
239	Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Human Molecular Genetics, 2005, 14, 2063-2073.	1.4	381
240	Â-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells. Journal of Neuroscience, 2005, 25, 5544-5552.	1.7	237
241	MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE. Annual Review of Neuroscience, 2005, 28, 57-87.	5.0	1,111
242	From The Cover: Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16842-16847.	3.3	1,084
243	Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. Molecular Brain Research, 2005, 134, 103-108.	2.5	71
244	To die or grow: Parkinson's disease and cancer. Trends in Neurosciences, 2005, 28, 348-352.	4.2	110
245	Recent advances in our understanding of Parkinson's disease. Drug Discovery Today Disease Mechanisms, 2005, 2, 427-433.	0.8	14
246	Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacological Research, 2005, 52, 5-14.	3.1	218
247	Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Human Molecular Genetics, 2005, 14, 3801-3811.	1.4	321
248	Genetics Of Parkinsonâ€™s Disease. Neurological Disease and Therapy, 2005, , 611-631.	0.0	0
249	Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17699-17704.	3.3	285
250	Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10744-10749.	3.3	317
251	Identification of calcium- and nitric oxide-regulated genes by differential analysis of library expression (DAzLE). Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 647-652.	3.3	32
252	BAD Is a Pro-survival Factor Prior to Activation of Its Pro-apoptotic Function. Journal of Biological Chemistry, 2004, 279, 42240-42249.	1.6	48

#	ARTICLE	IF	CITATIONS
253	Identification and analysis of plasticity-induced late-response genes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2145-2150.	3.3	57
254	Maiming mitochondria in familial ALS. Nature Medicine, 2004, 10, 905-906.	15.2	9
255	Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene, 2004, 23, 2785-2796.	2.6	490
256	PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. Journal of Neurochemistry, 2004, 90, 1068-1075.	2.1	266
257	Deadly Conversations: Nuclear-Mitochondrial Cross-Talk. Journal of Bioenergetics and Biomembranes, 2004, 36, 287-294.	1.0	169
258	Parkin-associated Parkinsonâ€™s disease. Cell and Tissue Research, 2004, 318, 175-184.	1.5	126
259	Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. Hepatology, 2004, 39, 403-411.	3.6	141
260	S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function. Science, 2004, 304, 1328-1331.	6.0	736
261	Apoptosis-Inducing Factor Substitutes for Caspase Executioners in NMDA-Triggered Excitotoxic Neuronal Death. Journal of Neuroscience, 2004, 24, 10963-10973.	1.7	258
262	Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends in Pharmacological Sciences, 2004, 25, 259-264.	4.0	423
263	Genomics-Proteomics and Stroke: Introduction. Stroke, 2004, 35, 2731-2734.	1.0	3
264	What have Genetically Engineered Mice Taught Us About Ischemic Injury?. Current Molecular Medicine, 2004, 4, 207-225.	0.6	14
265	Intracellular Signaling: Mediators and Protective Responses. , 2004, , 895-902.		0
266	Role for the Ubiquitin-Proteasome System in Parkinson's Disease and Other Neurodegenerative Brain Amyloidoses. NeuroMolecular Medicine, 2003, 4, 95-108.	1.8	50
267	New insights into Parkinson?s disease. Journal of Neurology, 2003, 250, 1-1.	1.8	37
268	Genetics of Parkinson's disease: What do mutations in DJ-1 tell us?. Annals of Neurology, 2003, 54, 281-282.	2.8	14
269	Involvement of poly ADP ribosyl polymerase-1 in acute but not chronic zinc toxicity. European Journal of Neuroscience, 2003, 18, 1402-1409.	1.2	39
270	A missense mutation (L166P) in DJâ€1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homoâ€oligomerization. Journal of Neurochemistry, 2003, 87, 1558-1567.	2.1	198

#	ARTICLE	IF	CITATIONS
271	Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. Neurobiology of Disease, 2003, 14, 303-317.	2.1	185
272	Poly (ADP-ribose) polymerase and brain ischemia. International Congress Series, 2003, 1252, 21-29.	0.2	0
273	Molecular Pathways of Neurodegeneration in Parkinson's Disease. Science, 2003, 302, 819-822.	6.0	1,530
274	37-kDa Laminin Receptor Precursor Modulates Cytotoxic Necrotizing Factor 1â€"mediated RhoA Activation and Bacterial Uptake. Journal of Biological Chemistry, 2003, 278, 16857-16862.	1.6	106
275	Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age. Journal of Biological Chemistry, 2003, 278, 48120-48128.	1.6	140
276	Nuclear Localization of a Non-caspase Truncation Product of Atrophin-1, with an Expanded Polyglutamine Repeat, Increases Cellular Toxicity. Journal of Biological Chemistry, 2003, 278, 13047-13055.	1.6	78
277	The Cast of Molecular Characters in Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 80-92.	1.8	35
278	Apoptosis Inducing Factor and PARPâ€Mediated Injury in the MPTP Mouse Model of Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 132-139.	1.8	112
279	Rare genetic mutations shed light on the pathogenesis of Parkinson disease. Journal of Clinical Investigation, 2003, 111, 145-151.	3.9	91
280	Rare genetic mutations shed light on the pathogenesis of Parkinson disease. Journal of Clinical Investigation, 2003, 111, 145-151.	3.9	175
281	The Orphan Nuclear Receptor, Steroidogenic Factor 1, Regulates Neuronal Nitric Oxide Synthase Gene Expression in Pituitary Gonadotropes. Molecular Endocrinology, 2002, 16, 2828-2839.	3.7	27
282	Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. Journal of Cell Biology, 2002, 158, 507-517.	2.3	434
283	Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor. Science, 2002, 297, 259-263.	6.0	1,671
284	Mechanisms of ischemic tolerance. , 2002, , 58-71.		0
285	Poly(ADP-Ribose) Polymerase Impairs Early and Long-Term Experimental Stroke Recovery. Stroke, 2002, 33, 1101-1106.	1.0	123
286	The genetics of Parkinsonâ€™s disease. Current Neurology and Neuroscience Reports, 2002, 2, 439-446.	2.0	27
287	A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism. Journal of Neurochemistry, 2002, 83, 186-192.	2.1	75
288	Neuroprotective and neurorestorative strategies for Parkinson's disease. Nature Neuroscience, 2002, 5, 1058-1061.	7.1	152

#	ARTICLE	IF	CITATIONS
289	Gene therapy to the rescue in Parkinson's disease. Trends in Pharmacological Sciences, 2001, 22, 103-105.	4.0	4
290	The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends in Neurosciences, 2001, 24, S7-S14.	4.2	184
291	The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends in Neurosciences, 2001, 24, 7-14.	4.2	161
292	Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity. Science, 2001, 291, 2423-2428.	6.0	1,035
293	Neuroprotective Effect of Ïƒ ₁ -Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine (PPBP) Is Linked to Reduced Neuronal Nitric Oxide Production. Stroke, 2001, 32, 1613-1620.	1.0	83
294	Reduction of functional N-methyl-d-aspartate receptors in neurons by RNase P-mediated cleavage of the NR1 mRNA. Journal of Neurochemistry, 2001, 76, 1386-1394.	2.1	8
295	Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. European Journal of Neuroscience, 2001, 13, 1683-1693.	1.2	87
296	Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets. Annals of Neurology, 2001, 50, 6-16.	2.8	85
297	Parkin ubiquitinates the Î±-synucleinâ€“interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nature Medicine, 2001, 7, 1144-1150.	15.2	710
298	Parkin: clinical aspects and neurobiology. Clinical Neuroscience Research, 2001, 1, 467-482.	0.8	15
299	FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 2425-2430.	3.3	128
300	Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Human Molecular Genetics, 2001, 10, 919-926.	1.4	442
301	Brain serotonin dysfunction accounts for aggression in male mice lacking neuronal nitric oxide synthase. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1277-81.	3.3	99
302	NMDA But Not Non-NMDA Excitotoxicity is Mediated by Poly(ADP-Ribose) Polymerase. Journal of Neuroscience, 2000, 20, 8005-8011.	1.7	206
303	Stroke Outcome in Double-Mutant Antioxidant Transgenic Mice. Stroke, 2000, 31, 2685-2691.	1.0	44
304	Requirement for nitric oxide activation of p21ras/extracellular regulated kinase in neuronal ischemic preconditioning. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 436-441.	3.3	317
305	Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13354-13359.	3.3	916
306	Dynamic regulation of neuronal NO synthase transcription by calcium influx through a CREB family transcription factor-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8617-8622.	3.3	168

#	ARTICLE	IF	CITATIONS
307	Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease. Neurobiology of Disease, 2000, 7, 240-250.	2.1	397
308	Neuronal ischaemic preconditioning. Trends in Pharmacological Sciences, 2000, 21, 423-424.	4.0	55
309	Influence of Nitric Oxide on Neuroendocrine Function and Behavior. , 2000, , 429-438.		4
310	Neurotoxic Actions and Mechanisms of Nitric Oxide. , 2000, , 695-710.		5
311	Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5774-5779.	3.3	365
312	Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Medicine, 1999, 5, 1403-1409.	15.2	1,007
313	Synphilin-1 associates with Î±-synuclein and promotes the formation of cytosolic inclusions. Nature Genetics, 1999, 22, 110-114.	9.4	473
314	Role of neuronal and endothelial nitric oxide synthase in nitric oxide generation in the brain following cerebral ischemia. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1999, 1455, 23-34.	1.8	129
315	Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis. Neuroscience, 1999, 90, 1483-1492.	1.1	81
316	Glutamate-stimulated calcium activation of Ras/Erk pathway mediated by nitric oxide. Diabetes Research and Clinical Practice, 1999, 45, 113-115.	1.1	33
317	Overview of the Pathway and Functions of Nitric Oxide. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 1999, 00, Unit 10.1.	1.1	0
318	Nuclear Targeting of Mutant Huntingtin Increases Toxicity. Molecular and Cellular Neurosciences, 1999, 14, 121-128.	1.0	177
319	Histochemical Analysis of Nitric Oxide Synthase by NADPH Diaphorase Staining. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 1999, 1, Unit 10.6.	1.1	7
320	Neuroprotective FK506 Does Not Alter In Vivo Nitric Oxide Production During Ischemia and Early Reperfusion in Rats. Stroke, 1999, 30, 1279-1285.	1.0	56
321	In vitro and in vivo effects of genistein on murine alveolar macrophage TNF alpha production. Cellular and Molecular Neurobiology, 1998, 18, 667-682.	1.7	217
322	Free Radicals as Mediators of Neuronal Injury. Cellular and Molecular Neurobiology, 1998, 18, 667-682.	1.7	208
323	Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Human Molecular Genetics, 1998, 7, 783-790.	1.4	329
324	mdx muscle pathology is independent of nNOS perturbation. Human Molecular Genetics, 1998, 7, 823-829.	1.4	99

#	Article	IF	Citations
325	Chapter 15 Nitric oxide in neurodegeneration. Progress in Brain Research, 1998, 118, 215-229.	0.9	336
326	Nitric oxide mediates N-methyl-D-aspartate receptor-induced activation of p21ras. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 5773-5778.	3.3	192
327	Nitric Oxide: Diverse Actions in the Central and Peripheral Nervous Systems. Neuroscientist, 1998, 4, 96-112.	2.6	20
328	Impaired Ovulation in Mice with Targeted Deletion of the Neuronal Isoform of Nitric Oxide Synthase. Molecular Medicine, 1998, 4, 658-664.	1.9	22
329	Manganese Superoxide Dismutase Protects nNOS Neurons from NMDA and Nitric Oxide-Mediated Neurotoxicity. Journal of Neuroscience, 1998, 18, 2040-2055.	1.7	258
330	Neuronal (type I) nitric oxide synthase regulates nuclear factorÂB activity and immunologic (type II) nitric oxide synthase expression. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 2676-2680.	3.3	187
331	Differential Susceptibility to Neurotoxicity Mediated by Neurotrophins and Neuronal Nitric Oxide Synthase. Journal of Neuroscience, 1997, 17, 4633-4641.	1.7	98
332	Inhibition of Neuronal Nitric Oxide Synthase Increases Aggressive Behavior in Mice. Molecular Medicine, 1997, 3, 610-616.	1.9	94
333	Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. Nature Medicine, 1997, 3, 571-574.	15.2	138
334	Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nature Medicine, 1997, 3, 1089-1095.	15.2	1,002
335	Aggressive behavior in male mice lacking the gene for neuronal nitric oxide synthase requires testosterone. Brain Research, 1997, 769, 66-70.	1.1	62
336	Effects of Nitric Oxide on Neuroendocrine Function and Behavior. Frontiers in Neuroendocrinology, 1997, 18, 463-491.	2.5	107
337	Nitric Oxide Synthase in Models of Focal Ischemia. Stroke, 1997, 28, 1283-1288.	1.0	578
338	NITRIC OXIDE SYNTHASE: Role as a Transmitter/Mediator in the Brain and Endocrine System. Annual Review of Medicine, 1996, 47, 219-227.	5.0	141
339	Nitric oxide neurotoxicity. Journal of Chemical Neuroanatomy, 1996, 10, 179-190.	1.0	460
340	NITRIC OXIDE ACTIONS IN NEUROCHEMISTRY. Neurochemistry International, 1996, 29, 97-110.	1.9	174
341	Immunologic NO Synthase: Elevation in Severe AIDS Dementia and Induction by HIV-1 gp41. Science, 1996, 274, 1917-1921.	6.0	410
342	Nitric Oxide Synthase Inhibitors. CNS Drugs, 1996, 6, 351-357.	2.7	10

#	ARTICLE	IF	CITATIONS
343	NADPH Diaphorase Staining. Methods in Neurosciences, 1996, 31, 62-67.	0.5	2
344	Function of Nitric Oxide in Neuronal Cell Death. Methods in Neurosciences, 1996, , 228-240.	0.5	2
345	Nitric Oxide Toxicity in Central Nervous System Cultures. Methods in Neurosciences, 1996, 30, 26-43.	0.5	4
346	Generation of isoform-specific antibodies to nitric oxide synthases. Methods in Enzymology, 1996, 268, 349-358.	0.4	4
347	Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 5037-5042.	3.3	145
348	Nitric Oxide in Neuronal Degeneration. Experimental Biology and Medicine, 1996, 211, 33-40.	1.1	120
349	Neurobiology of Nitric Oxide. Critical Reviews in Neurobiology, 1996, 10, 291-316.	3.3	255
350	Nitric Oxide Actions in the Nervous System. , 1996, , 247-262.		0
351	Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. Annals of Neurology, 1995, 37, 115-118.	2.8	68
352	Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature, 1995, 378, 383-386.	13.7	606
353	NITRIC OXIDE: ROLE IN NEUROTOXICITY. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 305-308.	0.9	126
354	REVIEW â–: Nitric Oxide: Actions and Pathological Roles. Neuroscientist, 1995, 1, 7-18.	2.6	100
355	Physiological and Toxicological Actions of Nitric Oxide in the Central Nervous System. Advances in Pharmacology, 1995, 34, 323-342.	1.2	62
356	Nitric Oxide Neurotoxicity in Primary Neuronal Cultures. , 1995, , 3-15.		0
357	Receptor Alterations in Subcortical Structures after Bilateral Middle Cerebral Artery Infarction of the Cerebral Cortex. Experimental Neurology, 1994, 128, 88-96.	2.0	13
358	Cyclic nucleotide dependent phosphorylation of neuronal nitric oxide synthase inhibits catalytic activity. Neuropharmacology, 1994, 33, 1245-1251.	2.0	134
359	Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology, 1994, 33, 1425-1430.	2.0	237
360	gp120 neurotoxicity in primary cortical cultures. Advances in Neuroimmunology, 1994, 4, 167-173.	1.8	24

#	Article	IF	Citations
361	Molecular Mechanisms of Nitric Oxide Actions in the Brain^a. Annals of the New York Academy of Sciences, 1994, 738, 76-85.	1.8	103
362	Alterations in cortical muscarinic receptors following cholinotoxin (AF64A) lesion of the rat nucleus basalis magnocellularis. Neurobiology of Aging, 1992, 13, 25-32.	1.5	22
363	A novel neuronal messenger molecule in brain: The free radical, nitric oxide. Annals of Neurology, 1992, 32, 297-311.	2.8	837
364	Functional recovery of supersensitive dopamine receptors after intrastriatal grafts of fetal substantia nigra. Experimental Neurology, 1991, 111, 282-292.	2.0	68
365	Downregulation of muscarinic receptors in the rat caudate-putamen after lesioning of the ipsilateral nigrostriatal dopamine pathway with 6-hydroxydopamine (6-OHDA): normalization by fetal mesencephalic transplants. Brain Research, 1991, 540, 145-152.	1.1	22
366	Reversal of Nigrostriatal-Lesion-Induced Receptor Alterations by Grafting of Fetal Mesencephalic Dopaminergic Neurons. Advances in Experimental Medicine and Biology, 1991, 287, 221-235.	0.8	0
367	Characterization of polyamines having agonist, antagonist, and inverse agonist effects at the polyamine recognition site of the NMDA receptor. Neuron, 1990, 5, 199-208.	3.8	174
368	Hippocampal muscarinic supersensitivity after AF64A medial septal lesion excludes M1 receptors. Brain Research Bulletin, 1990, 25, 311-317.	1.4	17
369	Muscarinic and dopaminergic receptor subtypes on striatal cholinergic interneurons. Brain Research Bulletin, 1990, 25, 903-912.	1.4	36
370	Normalization of subtype-specific muscarinic receptor binding in the denervated hippocampus by septodiagonal band grafts. Experimental Neurology, 1989, 106, 115-124.	2.0	63
371	Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen. Life Sciences, 1988, 42, 1933-1939.	2.0	77